<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 7-month-old infant with Tetralogy of Fallot is brought to the emergency department by her parents because of a 1-day history of fever, cough, and difficulty breathing. She was born at 29 weeks of gestation. Her routine immunizations are up-to-date. She is currently in the 4th percentile for length and 2nd percentile for weight. She appears ill. Her temperature is 39.1C 102.3F. Physical examination shows diffuse wheezing, subcostal retractions, and bluish discoloration of the fingertips. Administration of which of the following would most likely have prevented this patients current condition?? A: Ribavirin, B: Oseltamivir, C: Ganciclovir, D: Ceftriaxone, E: Palivizumab,  <response>: This is a question about preventing a respiratory infection in an infant with Tetralogy of Fallot, a congenital heart defect. The infant is 7 months old, premature, small for age, and has fever, cough, wheezing, and breathing difficulties indicating a respiratory infection. The key information is that the infant has Tetralogy of Fallot, a congenital heart defect that puts infants at higher risk of respiratory infections. The question asks which medication would most likely have prevented the current respiratory infection.Palivizumab choice E is a monoclonal antibody that provides passive immunity against respiratory syncytial virus RSV and is used to prevent RSV infections in high-risk infants. The other options are antiviral or antibiotic medications that would not be routinely given to prevent infections in an infant with congenital heart disease.E: Palivizumab 